RusnanoMedInvest specializes in investing in the development of innovative pharmaceutical technologies and products in Russia and worldwide.
We are interested in investment opportunities in promising new developments in the field of pharmaceuticals and medical equipment;
Our investment strategy and focus centers primarily around projects at the later stages of development, in particular compounds or products that have proven, market-relevant differentiated therapeutic efficacy, tolerability or safety in phase 2 or later or otherwise demonstrate game-changing potential with respect to patient welfare or healthcare economics.
Our portfolio companies:
Clearside Biomedical, Inc. (“Clearside”), (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be shared as a late-breaking oral presentation during the 2018 annual meeting of the American Society of Retina Specialists , July 20-25 in Vancouver, Canada .
11 July 2018
10 July 2018
21 June 2018